deucravacitinib
General
General
General
Pronunciation:
doo-krav-a-sye-ti-nib
Trade Name(s)
Ther. Class.
antipsoriatics
Pharm. Class.
kinase inhibitors
Indications
Indications
Indications
Moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
Action
Action
Action
Acts as a inhibitor of tyrosine kinase 2. Its exact mechanism for effect in plaque psoriasis is unknown.
Therapeutic Effect(s):
Decreased formation and spread of plaques.
Pharmacokinetics
Pharmacokinetics
Pharmacokinetics
Absorption: Well absorbed (99%) following oral administration.
Distribution: Extensively distributed to tissues.
Protein Binding: 82–90%.
Metabolism and Excretion: Primarily metabolized by the liver via the CYP1A2 isoenzyme to form an active metabolite (BMT-153261). Also metabolized by CYP2B6, CYP2D6, carboxylesterase 2, and UGT1A9. 26% and 13% excreted in feces and urine, respectively, as unchanged drug.
Half-life: 10 hr.
TIME/ACTION PROFILE (plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|
PO | unknown | 2–3 hr | 24 hr |
Contraindication/Precautions
Contraindication/Precautions
Contraindication/Precautions
Contraindicated in:
- Hypersensitivity;
- Active or serious infection (including tuberculosis [TB] and hepatitis B/C);
- Severe hepatic impairment.
Use Cautiously in:
- Chronic or recurrent infection, exposure to tuberculosis, history of opportunistic infection, underlying conditions that predispose to infection;
- Malignancy (other than successfully treated nonmelanoma skin cancer);
- OB: Safety not established in pregnancy;
- Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
- Pedi: Safety and effectiveness not established in children.
Adverse Reactions/Side Effects
Adverse Reactions/Side Effects
Adverse Reactions/Side Effects
Derm: acne
GI: ↑ liver enzymes, mouth ulcers
Metabolic: hypertriglyceridemia
MS: ↑ CK, RHABDOMYOLYSIS
Misc: INFECTION, HYPERSENSITIVITY REACTIONS (including angioedema), MALIGNANCY (including lymphoma)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Interactions
Interactions
Interactions
Drug-Drug
Avoid concurrent use with live vaccines.
Route/Dosage
Route/Dosage
Route/Dosage
PO (Adults): 6 mg once daily.
Availability
Availability
Availability
Tablets: 6 mg
Assessment
Assessment
Assessment
- Assess skin lesions and concurrent symptoms (absence of itch, pain, burning, stinging, and skin tightness) before and periodically during therapy.
- Monitor for signs and symptoms of hypersensitivity (angioedema). If symptoms occur, discontinue therapy.
- Assess for signs and symptoms of infection, especially pneumonia and COVID-19, during and after treatment. If serious infection occurs, discontinue therapy until infection resolved. If viral reactivation of herpes zoster or hepatitis B/C occurs, consult specialist.
Lab Test Considerations:
May cause rhabdomyolysis and asymptomatic CK ↑. If markedly ↑ CK occurs or myopathy suspected, discontinue deucravacitinib.
- Periodically evaluate serum triglycerides during therapy. May ↑ triglycerides.
- Consider viral hepatitis screening and monitoring for reactivation at baseline and during therapy.
- Assess liver enzymes at baseline and periodically during therapy in patients with known or suspected liver disease. If drug-induced ↑ in liver enzymes occurs, interrupt therapy until a diagnosis of liver injury is excluded.
Implementation
Implementation
Implementation
- Evaluate for acute and latent TB before starting therapy. For latent TB, initiate treatment before starting deucravacitinib. For active TB, do not administer deucravacitinib.
- Update age-appropriate immunizations before starting therapy, including herpes zoster vaccination. Avoid use of live vaccines during therapy.
- PO Administer tablet once daily without regard to food. DNC: Swallow tablets whole; do not break, crush, or chew.
Patient/Family Teaching
Patient/Family Teaching
Patient/Family Teaching
- Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
- Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
- Advise patient to notify health care professional and stop deucravacitinib immediately for serious hypersensitivity reactions (difficulty breathing; swelling of face, mouth, or neck).
- Advise patient to avoid live vaccines during therapy.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Inform patient that medication may ↑ risk of malignancy, including lymphomas.
- Caution patient to avoid crowds and persons with known infections. Notify health care professional immediately if symptoms of infection occur.
- Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. If pregnancy occurs, report pregnancies to the Bristol-Myers Squibb Company's Adverse Event reporting line: 1-800-721-5072.
Evaluation/Desired Outcomes
Evaluation/Desired Outcomes
Evaluation/Desired Outcomes
Absence or decrease in psoriatic symptoms.
© 2000–2025 Unbound Medicine, Inc. All rights reserved